NeoGenomics, Inc. (NEO)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 01:56PM EDT. Market open.
| Previous close | 13.71 |
| Open | 13.88 |
| Bid | 10.01 x 200 |
| Ask | 13.52 x 100 |
| Day's range | 13.43 - 13.97 |
| 52-week range | 11.03 - 21.22 |
| Volume | |
| Avg. volume | 732,934 |
| Market cap | 1.724B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.66 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.45 |
Business WireNeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
FT. MYERS, Fla., May 28, 2024--NeoGenomics will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at ASCO 2024 in Chicago (booth #31093).
Insider MonkeyNeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript April 30, 2024 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.03. NEO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the NeoGenomics First Quarter 2024 Financial […]
Simply Wall St.NeoGenomics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
NeoGenomics ( NASDAQ:NEO ) First Quarter 2024 Results Key Financial Results Revenue: US$156.2m (up 14% from 1Q 2023...
© 2024 Yahoo. All rights reserved.